GlassScriptPhysician profile
Claudio D Tuda
NPI 1497728620
$220,898.82
in general payments reported to CMS, 2019-2025
26 companies · $348 in 2025
The $348 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128K · 2020: $55K · 2021: $30K · 2022: $2,222 · 2023: $4,072 · 2024: $1,433 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,625 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,070.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,625.00 |
| Education | $156.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $140,681.48 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $65,089.17 | 2019-2025 | |
| Napo Pharmaceuticals INC | $4,268.74 | 2019-2021 | |
| Theratechnologies INC. | $4,163.65 | 2019-2023 | Egrifta, Trogarzo |
| Abbvie INC. | $1,403.66 | 2019-2025 | Avycaz, Dalvance, Teflaro |
| Allergan, INC. | $1,382.57 | 2019-2020 | |
| Janssen Biotech, INC. | $1,040.43 | 2019-2023 | Symtuza |
| Insmed, INC. | $750.56 | 2019-2024 | Arikayce |
| Merck Sharp & Dohme LLC | $576.76 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $287.97 | 2019-2023 | Xarelto |
| Astellas Pharma US INC | $243.26 | 2019-2023 | Cresemba |
| Janssen Products, LP | $198.00 | 2021 | |
| Shionogi INC | $173.27 | 2023-2025 | Fetroja |
| Tetraphase Pharmaceuticals, INC. | $121.36 | 2019 | |
| Emd Serono, INC. | $104.61 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $102.37 | 2021-2023 | Nuzyra |
| Melinta Therapeutics, LLC | $66.44 | 2022-2023 | Vabomere, Orbactiv, Kimyrsa |
| La Jolla Pharmaceutical Company | $47.52 | 2022 | |
| Pfizer INC. | $34.04 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $28.90 | 2025 | Vibativ |
| Vbi Vaccine (Delaware) INC. | $27.50 | 2023 | Prehevbrio |
| Horizon Therapeutics Plc | $24.95 | 2021 | |
| Ferring Pharmaceuticals INC. | $24.19 | 2023 | Rebyota |
| Glaxosmithkline, LLC. | $22.41 | 2023 | Shingrix, Arexvy |
| Mayne Pharma Commercial LLC | $22.10 | 2021 | |
| Nabriva Therapeutics, Plc | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudio Tuda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.